Arginase-1 is a promising new drug target for cancer immunotherapy. A novel assay technology for High-Throughput Screening (HTS) of Arginase-1 has been published in SLAS Discovery by researchers from NTRC in collaboration with Pivot Park Screening Centre (PPSC). The assay technology is known as Arginase Gold™.
NTRC is a precision medicine company dedicated to discovering new anti-cancer drug candidates. It is their mission to help you finding a mechanistic hypothesis before entering the clinic. NIRC provides cell-based profiling services, target residence time measurements, biochemical profiling and more.
Pivot Park Screening Centre (PPSC) provides drug discovery services in the field of assay development, lab automation, Ultra-High-Throughput Screening (uHTS) and hit-2-lead testing to find novel leads for drug development.
The enzyme Arginase-1 has a regulatory role in T cell and natural killer cell-mediated immunity in the tumor microenvironment by decreasing levels of the amino acid L-arginine, which is critical for an effective anti-tumor immune response. Preclinical studies have shown that inhibition of Arginase-1 increases tumor immune cell infiltration and decreases tumor growth in model systems for cancer. The first small molecule Arginase-1 inhibitor CB-1158 (INCB001158) is currently being investigated in clinical trials for the treatment of advanced and metastatic tumors as a single agent, and in combination with chemotherapy, immune checkpoint therapy and the IDO1 inhibitor epacadostat.